Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice
Open Access
- 26 May 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 6 (5), e1000083
- https://doi.org/10.1371/journal.pmed.1000083
Abstract
The loss of dystrophin compromises muscle cell membrane stability and causes Duchenne muscular dystrophy and/or various forms of cardiomyopathy. Increased expression of the dystrophin homolog utrophin by gene delivery or pharmacologic up-regulation has been demonstrated to restore membrane integrity and improve the phenotype in the dystrophin-deficient mdx mouse. However, the lack of a viable therapy in humans predicates the need to explore alternative methods to combat dystrophin deficiency. We investigated whether systemic administration of recombinant full-length utrophin (Utr) or ΔR4-21 “micro” utrophin (μUtr) protein modified with the cell-penetrating TAT protein transduction domain could attenuate the phenotype of mdx mice. Recombinant TAT-Utr and TAT-μUtr proteins were expressed using the baculovirus system and purified using FLAG-affinity chromatography. Age-matched mdx mice received six twice-weekly intraperitoneal injections of either recombinant protein or PBS. Three days after the final injection, mice were analyzed for several phenotypic parameters of dystrophin deficiency. Injected TAT-μUtr transduced all tissues examined, integrated with members of the dystrophin complex, reduced serum levels of creatine kinase (11,290±920 U versus 5,950±1,120 U; PBS versus TAT), the prevalence of muscle degeneration/regeneration (54%±5% versus 37%±4% of centrally nucleated fibers; PBS versus TAT), the susceptibility to eccentric contraction-induced force drop (72%±5% versus 40%±8% drop; PBS versus TAT), and increased specific force production (9.7±1.1 N/cm2 versus 12.8±0.9 N/cm2; PBS versus TAT). These results are, to our knowledge, the first to establish the efficacy and feasibility of TAT-utrophin-based constructs as a novel direct protein-replacement therapy for the treatment of skeletal and cardiac muscle diseases caused by loss of dystrophin.Keywords
This publication has 30 references indexed in Scilit:
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Effective Exon Skipping and Restoration of Dystrophin Expression by Peptide Nucleic Acid Antisense Oligonucleotides in mdx MiceMolecular Therapy, 2008
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Cytoplasmic γ-Actin Is Not Required for Skeletal Muscle Development but Its Absence Leads to a Progressive MyopathyDevelopmental Cell, 2006
- Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) for the Identification and Analysis of Multiprotein ComplexesScience's STKE, 2006
- Molecular and cellular contractile dysfunction of dystrophic muscle from young miceMuscle & Nerve, 2006
- Minigenes encoding N‐terminal domains of human cardiac myosin light chain‐1 improve heart function of transgenic ratsThe FASEB Journal, 2006
- Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon SkippingScience, 2004
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999